Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction

Jennifer B. Christian, John K. Finkle, Bonnie Ky, Pamela S. Douglas, David E. Gutstein, Paul D. Hockings, Pierre Lainee, Daniel J. Lenihan, Jay W. Mason, Philip T. Sager, Thomas G. Todaro, Karen A. Hicks, Robert C. Kane, Hon Sum Ko, Joann Lindenfeld, Eric L. Michelson, James Milligan, Jiefen Y. Munley, Joel S. Raichlen, Amir ShahlaeeColette Strnadova, Brenda Ye, J. Rick Turner

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


The ability to make informed benefit-risk assessments for potentially cardiotoxic new compounds is of considerable interest and importance at the public health, drug development, and individual patient levels. Cardiac imaging approaches in the evaluation of drug-induced myocardial dysfunction will likely play an increasing role. However, the optimal choice of myocardial imaging modality and the recommended frequency of monitoring are undefined. These decisions are complicated by the array of imaging techniques, which have varying sensitivities, specificities, availabilities, local expertise, safety, and costs, and by the variable time-course of tissue damage, functional myocardial depression, or recovery of function. This White Paper summarizes scientific discussions of members of the Cardiac Safety Research Consortium on the main factors to consider when selecting nonclinical and clinical cardiac function imaging techniques in drug development. We focus on 3 commonly used imaging modalities in the evaluation of cardiac function: echocardiography, magnetic resonance imaging, and radionuclide (nuclear) imaging and highlight areas for future research.

Original languageEnglish
Pages (from-to)846-855
Number of pages10
JournalAmerican Heart Journal
Issue number6
StatePublished - Dec 2012
Externally publishedYes


Dive into the research topics of 'Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction'. Together they form a unique fingerprint.

Cite this